Akari Therapeutics PlcAKTX
Price (close)
$9.76
Market cap
$19.0M
P/E
—
Revenue (TTM)
—
Net income
-$31.0M
Dividend yield
—
1-year total return
-78.2%
Net margin
—
Revenue growth
—
Debt / equity
—
What Akari Therapeutics Plc does.
payloads utilizing powerful biology to attack cancer. Our lead payload, PH1, targets RNA splicing by modulating the spliceosome, a
complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and
cytotoxicity that causes cancer cell death and 2) generates neoantigen proteins that activates both the innate and adaptive immune
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$17.1M | -$17.4M | -$17.7M | -$10.0M | -$19.8M | -$17.3M |
| Free cash flow | — | — | — | — | — | — |
More on AKTX.
- Akari Therapeutics Plc summary
- Akari Therapeutics Plc financial statements
- Akari Therapeutics Plc key metrics
- Akari Therapeutics Plc health scores and style box
- Akari Therapeutics Plc earnings
- Akari Therapeutics Plc dividends
- Akari Therapeutics Plc valuation
- Akari Therapeutics Plc ownership and insiders
- Akari Therapeutics Plc peers
Figures from Akari Therapeutics Plc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.